Integrative Analysis of HTNV Glycoprotein Derived MHC II Epitopes by <i>In Silico</i> Prediction and Experimental Validation
Hao Sun,Zhenhua Lu,Guoyun Xuan,Ning Liu,Tianhu Wang,Yang Liu,Mingfu Lan,Jiahao Xu,Yuancai Feng,Shuang Xu,Yuchen Lu,Baozeng Sun,Jinpeng Zhang,Xiyang Zhang,Yuanjie Sun,Shuya Yang,Yun Zhang,Yusi Zhang,Linfeng Cheng,Dongbo Jiang,Kun Yang
DOI: https://doi.org/10.3389/fcimb.2021.671694
IF: 6.073
2021-01-01
Frontiers in Cellular and Infection Microbiology
Abstract:Hantaan virus (HTNV), the causative pathogen of hemorrhagic fever with renal syndrome (HFRS), is a negative RNA virus belonging to the Orthohantaviridae family. HTNV envelope glycoprotein (GP), encoded by the genomic medium segment, is immunogenic and is therefore a promising vaccine candidate. Major histocompatibility complex class I (MHC-I) epitopes derived from HTNV has been extensively studied, but little is known of MHC-II epitopes. In silico predictions based on four databases indicated that the full-length HTNV GP has 1121 15-mer epitopes, of which 289 had a high score for binding to the human and murine MHC-II superfamily. It found that epitope ILTVLKFIANIFHTS could potentially bind most MHC-II molecules covering human and murine haplotypes. Dominant epitopes were validated by enzyme-linked immunospot assay of splenocytes from immunized mice; 6 of 10 epitopes supported the predictions including TATYSIVGPANAKVP, TKTLVIGQCIYTITS, FSLLPGVAHSIAVEL, CETYKELKAHGVSCP, CGLYLDRLKPVGSAY, and NLGENPCKIGLQTSS. Conservation analysis of dominant epitopes revealed host-virus interactions without geographic stratification, thus meeting the requirements of candidate vaccines for large-population prophylaxis. These findings provide insight into hantavirus antigenicity and suggest that vaccines targeting MHC-II could provide immune protection in large population to complement symptomatic therapies for the treatment of HFRS.